About: NanOlogy
Profile:
Posts by NanOlogy:
- NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer (March 7, 2023 - Home Page, NanOlogy Press Release)
- NanOlogy General Presentation (January 2023) (January 6, 2023 - Presentations)
- NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts (December 20, 2022 - NanOlogy Press Release)
- Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts (December 15, 2022 - Publications)
- NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer (November 11, 2022 - Home Page, NanOlogy Press Release)
- NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX (September 20, 2022 - Home Page, NanOlogy Press Release)
- Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies (September 6, 2022 - Publications)
- DDW 2022 Poster: The Efficacy of Intracystic Injection of Large Surface Area Microparticle Paclitaxel (NanoPac®) in the Management of Intraductal Papillary Mucinous Neoplasms: Results from an Expanded Access Protocol (August 6, 2022 - Presentations)
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer (August 1, 2022 - Home Page, NanOlogy Press Release)
- Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery (July 27, 2022 - Publications)
- Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions (May 12, 2022 - Publications)
- NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer (May 3, 2022 - Home Page, NanOlogy Press Release)
- Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer (April 26, 2022 - Publications)
- Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care (November 9, 2021 - Home Page, NanOlogy Press Release)
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac) (November 3, 2021 - Presentations)
- OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach (September 16, 2021 - NanOlogy in the News)
- Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC (September 16, 2021 - NanOlogy in the News)
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions (August 24, 2021 - Home Page, Publications)
